Exenatide (exendin-4) studies: 530 papers with results
Page 5 of 11
- Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects.
Keller J · Regulatory peptides · 2012
Randomized controlled trial · 6 results
- Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes.
Bi Y · Acta diabetologica · 2014
Randomized controlled trial · 15 results
- A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes.
Fayfman M · Diabetes care · 2019
Randomized controlled trial · 13 results
- Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus.
Kothare PA · Journal of clinical pharmacology · 2008
Randomized controlled trial · 8 results
- Investigation of the haemodynamic effects of exenatide in healthy male subjects.
Mendis B · British journal of clinical pharmacology · 2012
Randomized controlled trial · 5 results
- Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.
Best JH · Diabetes care · 2011
Randomized controlled trial · 12 results
- Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes.
Kadowaki T · Endocrine journal · 2009
Randomized controlled trial · 15 results
- Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers.
Gurkan E · Diabetes research and clinical practice · 2014
Randomized controlled trial · 8 results
- Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL).
Bethel MA · Diabetes care · 2019
Randomized controlled trial · 3 results
- Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
Frías JP · Diabetes, obesity & metabolism · 2018
Randomized controlled trial · 7 results
- The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.
Nelson P · Diabetes technology & therapeutics · 2007
Randomized controlled trial · 12 results
- Weight Loss Outcomes Among Early High Responders to Exenatide Treatment: A Randomized, Placebo Controlled Study in Overweight and Obese Women.
Rodgers M · Frontiers in endocrinology · 2021
Randomized controlled trial · 6 results
- Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes.
van Ruiten CC · The Journal of clinical endocrinology and metabolism · 2022
Randomized controlled trial · 3 results
- Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes.
Blevins T · Postgraduate medicine · 2010
Randomized controlled trial · 8 results
- Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
Meloni AR · Cardiovascular diabetology · 2013
Randomized controlled trial · 12 results
- Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.
Ferrannini E · Diabetes, obesity & metabolism · 2020
Randomized controlled trial · 13 results
- Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration.
Buse JB · Current medical research and opinion · 2014
Randomized controlled trial · 13 results
- Screening for Inflammatory Markers Identifies IL-18Rα as a Potential Link between Exenatide and Its Anti-Inflammatory Effect: New Results from the Combat-JUDO Randomized Controlled Trial.
Stenlid R · Annals of nutrition & metabolism · 2023
Randomized controlled trial · 3 results
- Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD.
Liu L · Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2023
Randomized controlled trial · 4 results
- The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes.
Retnakaran R · Cardiovascular diabetology · 2023
Randomized controlled trial · 16 results
- Exenatide induces an enhanced endogenous glucagon-like peptide-1 secretory response in patients receiving basal insulin.
Parikh M · The Journal of clinical endocrinology and metabolism · 2026
Randomized controlled trial · 16 results
- Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug-naïve type 2 diabetic patients.
Deng H · Journal of diabetes · 2019
Non-randomized trial · 9 results
- Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus.
Torimoto K · Cardiovascular diabetology · 2015
Non-randomized trial · 6 results
- Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder.
Angarita GA · Drug and alcohol dependence · 2021
Non-randomized trial · 5 results
- Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Blonde L · Diabetes, obesity & metabolism · 2006
Non-randomized trial · 10 results
- Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension.
Grech O · Eye (London, England) · 2024
Non-randomized trial · 4 results
- Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes.
Rosenstock J · Diabetes care · 2012
Non-randomized trial · 5 results
- Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
Grimm M · Postgraduate medicine · 2013
Non-randomized trial · 16 results
- Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.
Bergenstal RM · Diabetes, obesity & metabolism · 2013
Non-randomized trial · 14 results
- Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.
Taylor K · BMC endocrine disorders · 2011
Non-randomized trial · 12 results
- Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study.
Philis-Tsimikas A · Journal of diabetes and its complications · 2019
Non-randomized trial · 7 results
- Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Buse JB · Clinical therapeutics · 2007
Non-randomized trial · 13 results
- Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.
Wysham CH · Mayo Clinic proceedings · 2015
Non-randomized trial · 13 results
- Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin.
Riddle MC · Diabetes/metabolism research and reviews · 2006
Non-randomized trial · 8 results
- Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
Klonoff DC · Current medical research and opinion · 2008
Non-randomized trial · 16 results
- Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers.
Chiquette E · Vascular health and risk management · 2012
Non-randomized trial · 7 results
- Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study.
Wysham CH · BMJ open diabetes research & care · 2020
Non-randomized trial · 7 results
- Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.
Schernthaner G · Diabetes, obesity & metabolism · 2015
Non-randomized trial · 3 results
- Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study.
Henry RR · Diabetes technology & therapeutics · 2016
Non-randomized trial · 8 results
- Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
Norwood P · Clinical therapeutics · 2012
Non-randomized trial · 12 results
- Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.
Ratner RE · Diabetes, obesity & metabolism · 2006
Non-randomized trial · 11 results
- Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study.
Patti AM · Diabetes research and clinical practice · 2019
Non-randomized trial · 8 results
- Exenatide treatment increases serum irisin levels in patients with obesity and newly diagnosed type 2 diabetes.
Liu J · Journal of diabetes and its complications · 2016
Non-randomized trial · 3 results
- Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit.
Abuannadi M · Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2013
Non-randomized trial · 8 results
- Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans.
Koska J · Diabetes · 2015
Non-randomized trial · 9 results
- The Changes of Lipidomic Profiles Reveal Therapeutic Effects of Exenatide in Patients With Type 2 Diabetes.
Zhang L · Frontiers in endocrinology · 2022
Non-randomized trial · 6 results
- Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients.
Camastra S · Diabetes, obesity & metabolism · 2017
Non-randomized trial · 17 results
- Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
Kolterman OG · The Journal of clinical endocrinology and metabolism · 2003
Non-randomized trial · 9 results
- Twelve weeks of exenatide treatment increases [18F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males.
Janssen LGM · Metabolism: clinical and experimental · 2020
Non-randomized trial · 10 results
- Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
Sathyanarayana P · Obesity (Silver Spring, Md.) · 2011
Non-randomized trial · 6 results